Ambros Therapeutics Adds Interim Analysis to Pain Trial
The FDA will allow an earlier look at clinical data during the Phase 3 trial for a complex regional pain syndrome treatment.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Should regulatory bodies accelerate clinical trial milestones to bring new treatments to patients more quickly?
Ambros Therapeutics reached alignment with the FDA to include an interim analysis in its Phase 3 CRPS-RISE trial for neridronate. This protocol change allows for a potential early stop to the study if the data warrants it.
Why it matters
The inclusion of an interim analysis provides the opportunity to reach a clinical decision for the potential treatment of complex regional pain syndrome type 1 significantly earlier than originally planned. Currently, there are no FDA-approved medications for the 65,000 Americans newly diagnosed with the condition each year.
The CRPS-RISE trial involves 270 participants randomized in a 1:1 ratio to receive either 400 mg of neridronate or a placebo via intravenous infusion. The primary efficacy endpoint measures the change in pain intensity on an 11-point scale at week 12.
The players
Ambros Therapeutics
A biotech company headquartered in San Diego that is developing neridronate for complex regional pain syndrome.
Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals and overseeing clinical trial protocols in the United States.
The details
The interim analysis will be conducted by an independent data monitoring committee once half of the study participants complete the trial. Ambros Therapeutics intends to submit a revised statistical analysis plan and Data Monitoring Committee charter to the FDA to formalize this change.
Timeline
Oct 26, 2026: Ambros Therapeutics announced the FDA alignment on the trial protocol.
Week 12: Participants undergo primary efficacy endpoint measurement.
The Tech Race
The CRPS-RISE trial marks a departure from standard clinical trial timelines by integrating an interim analysis to accelerate decision-making. This move positions neridronate as a frontrunner in the effort to fill the void for FDA-approved complex regional pain syndrome treatments.
Patients suffering from complex regional pain syndrome type 1 may benefit from a faster path to potential treatment availability if the interim analysis supports early success. However, trial outcomes remain pending until the study reaches its primary endpoint milestones.
The takeaway
This adjustment shows how companies are working with regulators to streamline the path for drugs that have already seen clinical use in other countries. It highlights the importance of adaptive trial designs in bringing new therapies to patients who currently lack FDA-approved options.
Further reading
For more on industry developments, visit the Biotech section.
More information
Review the full details in the clinicaltrials.gov trial record.
Source note: This article includes information reported by The Manila times.
Live Poll
Should regulatory bodies accelerate clinical trial milestones to bring new treatments to patients more quickly?
